Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2022

Investments, Debt and Equity Securities [Abstract]

The following table summarizes, by major security type, our cash, cash equivalents, restricted cash, and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in millions):


	December 31, 2021		March 31, 2022
	Total Estimated Fair Value		Cost or Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Total Estimated Fair Value
Cash	$	10,942	$	10,268	$	—	—		$	10,268
Level 1 securities:
Money market funds	20,312		23,858		—		—		23,858
Equity securities (1)(3)	1,646								9,121
Level 2 securities:
Foreign government and agency securities	181		50		—		(1)		49
U.S. government and agency securities	4,300		2,610		—		(97)		2,513
Corporate debt securities	35,764		17,097		—		(517)		16,580
Asset-backed securities	6,738		3,841		—		(116)		3,725
Other fixed income securities	686		409		—		(16)		393
Equity securities (1)(3)	15,740								87
	$	96,309	$	58,133	$	—	$	(747)	$	66,594
Less: Restricted cash, cash equivalents, and marketable securities (2)	(260)								(209)
Total cash, cash equivalents, and marketable securities	$	96,049							$	66,385

___________________

(1)The related unrealized gain (loss) recorded in “Other income (expense), net” was $3 million and $(8.1) billion in Q1 2021 and Q1 2022.

(2)We are required to pledge or otherwise restrict a portion of our cash, cash equivalents, and marketable fixed income securities primarily as collateral for real estate, amounts due to third-party sellers in certain jurisdictions, debt, and standby and trade letters of credit. We classify cash, cash equivalents, and marketable fixed income securities with use restrictions of less than twelve months as “Accounts receivable, net and other” and of twelve months or longer as non-current “Other assets” on our consolidated balance sheets. See “Note 4 — Commitments and Contingencies.”

(3)Our equity investment in Rivian had a fair value of $15.6 billion and $8.0 billion as of December 31, 2021 and March 31, 2022, respectively. The investment was subject to regulatory sales restrictions resulting in a discount for lack of marketability of approximately $800 million as of December 31, 2021, which expired in Q1 2022. In addition, we are subject to contractual sales restrictions that expire in May 2022.

Investments Classified by Contractual Maturity Date

The following table summarizes the remaining contractual maturities of our cash equivalents and marketable fixed income securities as of March 31, 2022 (in millions):


	Amortized Cost		Estimated Fair Value
Due within one year	$	29,151	$	29,144
Due after one year through five years	15,512		14,873
Due after five years through ten years	822		796
Due after ten years	2,380		2,305
Total	$	47,865	$	47,118

Consolidated Statements of Cash Flow Reconciliation - Cash and Cash Equivalents

The following table provides a reconciliation of the amount of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):


	December 31, 2021		March 31, 2022
Cash and cash equivalents	$	36,220	$	36,393
Restricted cash included in accounts receivable, net and other	242		191
Restricted cash included in other assets	15		15
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows	$	36,477	$	36,599

Consolidated Statements of Cash Flow Reconciliation - Restricted Cash


	December 31, 2021		March 31, 2022
Cash and cash equivalents	$	36,220	$	36,393
Restricted cash included in accounts receivable, net and other	242		191
Restricted cash included in other assets	15		15
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows	$	36,477	$	36,599